Kezhen L. Tang - Concepedia

Concepedia

Author

Kezhen L. Tang

Janssen (United States)

Also Known As

Kezhen L Tang, Kezhen L. Tang

22

Publications

6.9K

Citations

12

H-Index

21

Concepts

All Affiliations

Janssen (United States)Icahn School of Medicine at Mount Sinai Evangelismos Hospital Janssen Scientific Affairs (United States)University of California San Diego

KL

About

Kezhen L. Tang is an author at Janssen (United States) specializing in gastroenterology, medicine, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	522
2	Gastroenterology	4	4	522
3	Education	1	1	18
4	Engineering	1	1	18
5	Biostatistics	1	1	18

Kezhen L. Tang

×

12

Publications

6.9K

Citations

12

H-Index

	Year	Citations
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch, New England Journal of Medicine	2010	3.1K
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease Ajay Singh, Lynda A. Szczech, Kezhen L. Tang, New England Journal of Medicine	2006	2.7K
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial Freddy Cornillie, Stephen B. Hanauer, Robert H. Diamond, Gut	2014	369
Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease Jeffrey S. Hyams, Marla C. Dubinsky, Robert N. Baldassano, Gastroenterology InflammationAnti-inflammatoryImmunologyGastroenterologyPathology	2017	214
Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC Marc Ferrante, Jean‐Frédéric Colombel, William J. Sandborn, Gastroenterology Endoscopic Activity ScoresInterventional Endoscopic UltrasoundGastroenterologyDiagnosisOutcomes Research	2013	174
751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy William J. Sandborn, Paul Rutgeerts, Walter Reinisch, Gastroenterology InflammationDisease NaiveAnti-inflammatoryAutoimmune DiseaseImmunology	2009	117
Factors Associated With Short- and Long-Term Outcomes of Therapy for Crohn’s Disease Walter Reinisch, Jean‐Frédéric Colombel, William J. Sandborn, Clinical Gastroenterology and Hepatology	2014	81
Change in Erythrocyte Mean Corpuscular Volume During Combination Therapy with Azathioprine and Infliximab Is Associated with Mucosal Healing Guillaume Bouguen, Charles A. Sninsky, Kezhen L. Tang, Inflammatory Bowel Diseases	2015	41
Type I Error Rates for Yao’s and James Tests of Equality of Mean Vectors Under VarianceCovariance Heteroscedasticity James Algina, Kezhen L. Tang Journal of Educational Statistics ReliabilityStatistical ReviewVolatility ModelingEngineeringGeneralizability Theory	1988	18
Higher Levels of Infliximab may Alleviate the Need of Azathioprine Comedication in the Treatment of Patients with Crohn's Disease: A Sonic Post HOC Analysis Jean‐Frédéric Colombel, Omoniyi J. Adedokun, Christopher Gasink, Gastroenterology InflammationAnti-inflammatoryAzathioprine ComedicationAutoimmune DiseaseHigher Levels	2017	17

Page 1